MedTrace Logo

VENUS: Septic Gene Expression Using SeptiCyte

NCT02127502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 379

Last updated 2018-08-20

No results posted yet for this study

Summary

The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their being hospitalized in an intensive care unit (ICU) within the first 7 days of hospitalization. The primary purpose of the study is to validate SeptiCyte® Lab in this population as compared to: 1) the doctor's impression and 2) existing clinical parameters. The investigators also hope to assess how well a related, new blood test, SeptID® identifies different types of infection, as compared to cultures and other lab tests.

Conditions

  • Sepsis
  • Systemic Inflammatory Response Syndrome (SIRS)

Sponsors & Collaborators

  • Intermountain Health Care, Inc.

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Rush University Medical Center

    collaborator OTHER

  • Northwell Health

    collaborator OTHER

  • Loyola University

    collaborator OTHER

  • Grady Memorial Hospital

    collaborator OTHER

  • Immunexpress

    lead INDUSTRY

Principal Investigators

  • Russell R. Miller, MD, MPH · Intermountain Medical Center

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-08-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02127502 on ClinicalTrials.gov